Free Widgets | Feedback 
Live Share Markets - Appuonline.com


Updated:26 Sep 2017 03:31:00 PM(IST)

Investor Tool

My Stockwatch 

RELIANCE 820.10 [ -0.18% ]TCS 2474.65 [ -1.44% ]

Sensex31599.76
-26.87 -0.08%

Nifty9871.50
-1.10 -0.01%

Midcap15500.05
67.52 0.44%

Smallcap16136.28
173.15 1.08%



Lupin Ltd :

 1005.15  13.85 [1.40%]

ISIN: INE326A01037  | NSE: LUPIN |  Industry: Pharmaceuticals - Indian - Bulk Drugs  |  BSE Code: 500257  |  Add To Watchlist

Price Information
• Open 997.55
• High 1013.10
• Low 993.55
• Previous Close 991.30
• Shares Traded 10552000
• 52 Wk High Price 1572.25
• 52 Wk High Date 06-02-2017
• 52 Wk Low Price 920.00
• 52 Wk Low Date 21-08-2017
• Face Value 2.00


Fundamentals
• Market Capital (Rs.cr) 45791.90
• EPS (Rs.)(TTM) 53.54
• P/E Ratio(TTM) 18.94
• Book Value (Rs.) 327.10
• Price to Book Value 3.10
• Equity (Rs.cr.) 90.36
• Traded Value (Rs.lac) 1206.54


Corporate Actions
Ex-Date Purpose (Rs.)
2011-07-18 150% Dividend (3)
2012-07-13 160% Dividend (3.2)
2013-07-29 200% Dividend (4)
2014-02-13 150% Interim Dividend (3)
2014-07-21 150% Final dividend (3)
2015-07-14 375% Dividend (7.5)
2016-07-25 375% Dividend (7.5)
2017-07-24 375% Dividend (7.5)


Index Names
BSE-200
CNX Nifty
BSE Sensex
BSE HC
BSE-100
BSE-500


Related Companies
Stock Name Price
BHAGAWATIOXY 34.00




Key Financials Latest Qrtr. Trailing Yr. Full Yr.
• Year End Jun, 2017 Jun, 2017 Mar, 2017
• Sales (Rs.cr) 2437.74 11723.70 12753.20
• Net Profit (Rs.cr) 354.12 2418.95 3144.56
• Net Profit Var (%) -67.00 -25.00 12.00
• EPS (Rs) - 53.54 68.10
• P/E Ratio - 18.94 14.90
• Operating Profit Margin - 29.81 -
• CPS (Rs.) - - 76.20
• P/C Ratio - - 13.30
• Div% - - 375.00

Announcements
13-05-2015 Board of Lupin recommends final dividend
27-10-2015 Board of Lupin approves appoints director and CFO
28-06-2012 Lupin received final approval for Norgestimate and Ethinyl Estradiol tablets
02-08-2016 Lupin acquires branded product portfolio from Shionogi in Japan
25-02-2014 Lupin allot equity shares
23-06-2017 Lupin allots 22795 equity shares
29-05-2017 Lupin allots 30060 equity shares
23-02-2017 Lupin allots 34604 equity shares
24-03-2017 Lupin allots 46911 equity shares
22-08-2017 Lupin allots 49,309 equity shares
13-01-2017 Lupin allots 50081 equity shares
25-04-2017 Lupin allots 58569 equity shares
08-02-2011 Lupin allots equity share
06-12-2010 Lupin allots equity shares
03-11-2010 Lupin announces final USFDA approval for
23-10-2012 Lupin appoints additional director
11-08-2017 Lupin appoints Chairman
18-09-2017 Lupin appoints Chief Corporate Development Officer
11-07-2017 Lupin collaborates with The American Academy of Ophthalmology
16-03-2015 Lupin completes acquisition of Pharma Dynamics, South Africa
23-04-2014 Lupin enters strategic JV with Japanese pharma company
29-01-2015 Lupin gets approval for FII investment hike
22-05-2017 Lupin gets approval to market Bepotastine Tablets in India
27-08-2015 Lupin gets final approval for Omeprazole Delayed-Release capsules 40 mg
04-09-2012 Lupin gets UK MHRA nod for the Irbestran tablets
30-12-2013 Lupin grants ESOP
14-12-2010 Lupin grants options
08-01-2016 Lupin grants stock options
21-07-2017 Lupin intimates of successful PAI USFDA inspection of Goa facility
03-09-2015 Lupin launches first ever Duloxetine 40mg Delayed-Release Capsules
22-06-2017 Lupin launches Desoximetasone Cream in United States
15-11-2016 Lupin launches generic Activella® Tablets
16-05-2012 Lupin launches generic combivir tablets
07-03-2017 Lupin launches generic Paxil CR tablets
20-04-2015 Lupin launches Zaxine® in Canada
06-04-2016 Lupin named amongst AON Best Employers India
28-04-2016 Lupin re-introduces Methergine® Oral Tablets
16-09-2011 Lupin received final approval for the generic Lunesta
10-10-2011 Lupin received tentative approval for Irbestran tablets
31-10-2011 Lupin received tentative approval for the generic Combivir
07-07-2011 Lupin received tentative approval for the generic Lyrica
16-07-2014 Lupin receives Best Award for Learning & Development - 2014
05-07-2012 Lupin receives FDA approval for Generic LYRICA
19-10-2012 Lupin receives FDA approval for its Oral Contraceptive Kurvelo Tablets
16-02-2017 Lupin receives final approval for Moxifloxacin Hydrochloride Tablets
28-04-2017 Lupin receives final approval for Olmesartan Medoxomil tablets
31-01-2012 Lupin receives tentative approval for generic Extended Release Tablets
30-12-2014 Lupin receives tentative approval for generic Prezista® Tablets
08-05-2013 Lupin Recommends Dividend
26-07-2011 Lupin settles ongoing litigation with Medicis
12-09-2014 Lupin signs definitive distribution agreement with Salix Pharmaceuticals
26-04-2012 Lupin to announce financial results
13-07-2011 Lupin to announce Q1 results
10-10-2012 Lupin to announce Q2 results
12-01-2012 Lupin to announce Q3 results
11-07-2014 Lupin to hold AGM
25-01-2014 Lupin to hold board meeting

Gross Deliverables
Date Del. Shares Trd. Qty. Del.(%) Del. Value Turnover
25-09-2017 19371 79359 24.41 19202473 78709.00
22-09-2017 30903 117361 26.33 31321736 120654.00
21-09-2017 56880 292029 19.48 58725756 300727.00
20-09-2017 181187 239268 75.73 181585612 239626.00
19-09-2017 150790 261215 57.73 151664582 263823.00


Bulk Deals
Deal Date Client Name Type Qty Price
08-03-2016 GENESIS EMERGING MARKETS L P B 9423708 1816.67
08-03-2016 GENESIS INDIAN INVESTMENT COMPANY LIMITED S 9423708 1816.67


Block Deals
Deal Date Client Name Type Qty Price
12-08-2016 ZYMA LABORRATORIES LTD B 150000 1580.00
12-08-2016 DESHBANDHU GUPTA S 150000 1580.00
08-03-2016 NEW INDIA INVESTMENT TRUST PLC B 325000 1780.20
08-03-2016 NEW INDIA INVESTMENT COMPANY MAURITIUS LIMITED S 325000 1780.20
24-02-2016 ZYMA LABORRATORIES LTD B 300000 1770.00


Note:

- % change is w.r.t. Prev. Close
- On ex-date % change is w.r.t. open price
- On the date ofmovement of security from/to trade for trade segment, % change is w.r.t. open price
- 52 week high & 52 week low prices are based on the trade date & not adjusted with corporate action




Market on Mobile



Hot Searches  •  incab industries  •  oil india ltd  •  tvs ele  •  axis capi  •  tourism finance
Site Map  •  Companies  •  Learning Centre  •  Insurance  •  About  •  Contact us  •  Disclaimer
© appuonline.com

Content Provided by CMOTS InfoTech